KR101365794B1 - The improved composition for relieving hangovers and protecting a liver - Google Patents
The improved composition for relieving hangovers and protecting a liver Download PDFInfo
- Publication number
- KR101365794B1 KR101365794B1 KR1020120077942A KR20120077942A KR101365794B1 KR 101365794 B1 KR101365794 B1 KR 101365794B1 KR 1020120077942 A KR1020120077942 A KR 1020120077942A KR 20120077942 A KR20120077942 A KR 20120077942A KR 101365794 B1 KR101365794 B1 KR 101365794B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- composition
- extract
- alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 206010019133 Hangover Diseases 0.000 title claims abstract description 33
- 210000004185 liver Anatomy 0.000 title claims abstract description 23
- 230000002633 protecting effect Effects 0.000 title description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 53
- 210000004207 dermis Anatomy 0.000 claims abstract description 39
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 32
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 32
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 32
- 229940010454 licorice Drugs 0.000 claims abstract description 32
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229940043353 maltol Drugs 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 97
- 239000012676 herbal extract Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- -1 pH regulators Substances 0.000 claims description 11
- 241000411851 herbal medicine Species 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229920002230 Pectic acid Polymers 0.000 claims description 2
- 235000014676 Phragmites communis Nutrition 0.000 claims description 2
- 244000273256 Phragmites communis Species 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 235000014171 carbonated beverage Nutrition 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 5
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 claims 1
- 239000010318 polygalacturonic acid Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract description 26
- 230000035622 drinking Effects 0.000 abstract description 20
- 239000007788 liquid Substances 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 75
- 230000000052 comparative effect Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- 239000008213 purified water Substances 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 208000010706 fatty liver disease Diseases 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 206010019708 Hepatic steatosis Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 235000011511 Diospyros Nutrition 0.000 description 4
- 244000055850 Diospyros virginiana Species 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000024798 heartburn Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019997 soju Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDDWAYFUFNQLRZ-KJVHGCRFSA-N (3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)[C@@H](O)[C@@H](O)[C@]3(C)CC[C@]21C CDDWAYFUFNQLRZ-KJVHGCRFSA-N 0.000 description 1
- ZTVSGQPHMUYCRS-SWLSCSKDSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4h-benzo[f][1]benzofuran-2-one Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C=C1C2=C(C)C(=O)O1 ZTVSGQPHMUYCRS-SWLSCSKDSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 241000905368 Actaea rubra Species 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000141218 Alpinia officinarum Species 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 description 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 1
- 241000132011 Atractylodes lancea Species 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000000425 Chaenomeles speciosa Species 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- NGGOLDIRUNJLSH-UHFFFAOYSA-N Epialpinin Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C(OC)C(OC)=CC=C3C12 NGGOLDIRUNJLSH-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229910000004 White lead Inorganic materials 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000001774 alpinia officinarum Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- CDDWAYFUFNQLRZ-UHFFFAOYSA-N soyasapogenol A Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)C(O)C3(C)CCC21C CDDWAYFUFNQLRZ-UHFFFAOYSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 활성성분으로 양강, 진피, 갈근, 창출, 감초의 추출물과 말톨을 함유하는 것을 특징으로 하는 숙취해소 및 간 보호 조성물을 제공하는 것이며 액제, 정제, 과립제, 환제, 캡슐제, 껌의 제형으로 쉽게 음주 전 후에 섭취할 수 있다.The present invention provides a hangover and liver protection composition comprising the extract and maltol of Yanggang, dermis, root, create, licorice as an active ingredient and formulation of liquids, tablets, granules, pills, capsules, gum Easily consumed before and after drinking.
Description
본 발명은 생약추출물과 말톨을 유효성분으로 함유하는 숙취 해소 및 간 보호기능 개선용 조성물에 관한 것이다.The present invention relates to a composition for relieving hangovers and improving liver protection, containing herbal extracts and maltol as active ingredients.
알코올을 적당량 내지 소량을 섭취하면 혈액순환을 촉진하는 등의 양성적인 효과가 있으나, 과잉 섭취 또는 만성적으로 섭취할 경우 두통, 졸음, 갈증, 설사, 속쓰림, 오심, 구토, 오한, 식은땀, 구취, 기억 단절, 운동 능력 저하의 숙취 증상을 유발하거나 혈액학적 변화, 지방간 생성 등의 생리학적 증상을 유발한다.Ingesting an appropriate amount or a small amount of alcohol has a positive effect such as promoting blood circulation.However, ingestion or chronic intake may cause headache, drowsiness, thirst, diarrhea, heartburn, nausea, vomiting, chills, cold sweats, bad breath, It can cause hangover symptoms such as memory breakdown, decreased motor skills, or physiological symptoms such as hematological changes and fatty liver production.
숙취의 원인은 알코올 자체의 중추신경 억제 작용, 탈수, 알코올 및 알코올 대사산물인 아세트알데히드의 독성, 영양흡수 장애에 의한 영양소 결핍(혈당, 비타민, 무기질 결핍), 다량의 알코올을 대사시킬 때 생성되는 활성산소의 자유분자단으로 인한 지방 및 생체성분의 과산화, 또는 과산화 된 지방간을 환원시키기 위한 생체의 동원 능력 부하에 의한 것으로 알려져 있다.The hangover can be caused by the central nervous system depressant action of alcohol itself, dehydration, toxicity of alcohol and alcohol metabolite acetaldehyde, nutrient deficiency due to malnutrition (deficient blood sugar, vitamins, minerals), metabolism of large amounts of alcohol It is known to be due to the peroxidation of fat and biological components due to free molecular groups of free radicals, or the mobilization capacity of the living body to reduce peroxidized fatty liver.
최근에는 알코올(에탄올)에 소량 들어있는 메탄올의 대사 및 포름알데히드가 숙취의 원인으로 지적된 바 있으며, 실제 알코올에 의한 숙취는 알코올대사체인 아세트알데히드, 아세톤 등에 의한다는 것이 다수 보고되면서 새로운 연구 단계로 접어들고 있다(Moser J, Bagchi D, Akubue PI, Stohs SJ.. Alcohol Alcohol. 28:287-295, 1993). 일본에서는 미강 추출물의 대사 산물이 혈중 알코올 농도보다는 아세트알데히드 농도 저하에 더 크게 기여한다는 특허 내용이 있었으며 숙취 증상이 심한 사람이 숙취 증상이 적은 사람에 비해 아세트알데히드 농도는 높았으나 혈중 에탄올의 농도 차이는 거의 없었다는 보고(Wall TL, Horn SM, Johnson ML, Smith TL, Carr LG., JStud. Alcohol. 61:13-17, 2000)가 있어 알코올로 인한 숙취의 원인 물질이 아세트알데히드라는 데에 초점이 모이고 있다.Recently, methanol metabolism and formaldehyde in small amounts of alcohol (ethanol) have been pointed out as a cause of hangover, and actual hangover by alcohol is reported to be due to alcohol metabolism, acetaldehyde, acetone, etc. Entering (Moser J, Bagchi D, Akubue PI, Stohs SJ. Alcohol Alcohol. 28: 287-295, 1993). In Japan, there was a patent claim that metabolite of rice bran extract contributed to lower acetaldehyde concentration than blood alcohol level.In severe hangover patients, acetaldehyde concentration was higher than those with low hangover symptoms. There have been few reports (Wall TL, Horn SM, Johnson ML, Smith TL, Carr LG., JStud. Alcohol. 61: 13-17, 2000), focusing on acetaldehyde as the causative agent of alcohol-induced hangovers. have.
간은 인간의 신체 장기 중 생체 내 대사가 가장 활발하게 일어나는 장기로서, 지방 성분이 포함된 음식 또는 알코올의 과다 섭취, 바이러스의 감염, 각종 약품과 같은 유해물질, 영양부족 등 다양한 원인에 의해 급성 또는 만성의 장애가 일어나며, 이로 인해 지방간, 간염, 황달, 간경화, 간암 등이 야기될 수 있다. 특히 음식을 통한 과다한 지방 섭취 또는 과도한 알코올 섭취는 간 조직에 지질이 쌓이는 지방간을 유발하며, 이때 혈청 속의 GOT(glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase), γ-GTP(γ-glutamyltransferase) 등이 증가하게 된다. 간은 완충 능력이 큰 기관이므로 상기 질환의 초기단계에서는 잘 나타나지 않다가 병증이 상당히 악화된 후에야 상기 질환의 증상을 보이게 된다.The liver is one of the most active organs in the human body. It is caused by various causes such as excessive intake of food or alcohol containing fat ingredients, infection of viruses, harmful substances such as various medicines, and undernutrition. Chronic disorders occur, which can lead to fatty liver, hepatitis, jaundice, cirrhosis and liver cancer. In particular, excessive fat intake or excessive alcohol intake causes fatty liver to accumulate lipids in liver tissue. And so on. Since the liver is a large buffering organ, it does not show up well in the early stages of the disease, but only after the disease is significantly worsened.
또한, 간은 인체에서 혈액의 저장 및 순환, 혈류량 조절과 방어 해독작용을 하며 정신적 활동과 밀접하게 관련되어 있다고 알려져 있다. 인체는 산업화에 따른 공해 물질, 유독 물질에 항상 노출되어 있어, 간은 끊임없는 해독작용에 시달리고 있다. 더욱이, 심각한 것은 정신적인 스트레스로 인한 간 손상이다. 정신적 휴식을 가질 경우 손상된 간 세포는 복구되지만 급박한 현대사회에서는 정신적 휴식의 여유를 찾을 수 없기 때문에 정신적 스트레스, 과음, 흡연으로 간 손상을 가중시켜 인체가 방어 또는 해독작용을 하지 못하게 된다. 이는 면역체계에 이상을 가져와 다른 질병의 원인이 되기도 한다.In addition, the liver is known to be closely related to mental activity and to the blood storage and circulation, blood flow control and defense detoxification in the human body. The human body is always exposed to pollutants and toxic substances due to industrialization, and the liver suffers from constant detoxification. Moreover, what is serious is liver damage from mental stress. If you have a mental break, damaged liver cells will be repaired, but in an urgent modern society, you will not be able to afford mental rest. Therefore, mental stress, heavy drinking, and smoking will increase your liver damage, preventing your body from defending or detoxifying. This can cause abnormalities in the immune system and cause other diseases.
지속적인 알코올 섭취로 인한 알코올성 간 질환은 알코올성 지방간, 알코올성 간염 및 간경변증으로 나뉜다. 이중 지방간이 가장 흔한 편이나 때때로 이들 세 가지 질환은 서로 동시에 유발될 수 있다. Alcoholic liver disease due to continuous alcohol intake is divided into alcoholic fatty liver, alcoholic hepatitis and cirrhosis. Fatty liver is the most common, but sometimes these three diseases can occur at the same time.
알코올성 지방간은 간 조직에 지방세포들이 빽빽하게 들어 차있는 것을 말하며, 이러한 지방 축적은 주로 간에서 중성지방의 합성 증가, 지단백 합성 후의 혈중 분비 장애와 더불어 말초 지방 조직으로부터 유리된 지방이 간으로 유입되는 양에 비하여 지방산 산화 과정은 오히려 저하되기 때문에 생기는 것으로 알려져 있다.Alcoholic fatty liver is a high concentration of fat cells in the liver tissue, which is mainly due to the increased synthesis of triglycerides in the liver, impaired blood secretion after lipoprotein synthesis, and the amount of fat released from peripheral fatty tissue into the liver. Compared to this, fatty acid oxidation is known to occur because it is lowered.
알코올성 간염은 흔히 지방 세포의 침윤과 더불어 간 조직의 염증 반응과 섬유화가 일어나는 것을 말한다. 여기에 간세포가 죽어가는 괴사가 일어나고 딱딱한 결절이 형성된 상태를 알코올성 간경변증이라고 부른다. 알코올에 의한 지방간을 거쳐 간염이 진행되어 간경변으로 갈수록 교원질의 침착 정도가 많아져 섬유화의 정도도 높아지게 된다. 따라서 술에 의한 간질환은 음주량이 많을수록, 그리고 그 기간이 길수록 발생 위험률이 높아진다는 것은 누구나 쉽게 이해할 수 있으며 실제 여러 조사 결과들이 이를 뒷받침해주고 있다.Alcoholic hepatitis often refers to the infiltration of fat cells and the inflammatory response and fibrosis of liver tissues. Necrosis of dying liver cells and formation of hard nodules is called alcoholic cirrhosis. Hepatitis progresses through fatty liver due to alcohol, and as the cirrhosis increases, the degree of collagen deposition increases and the degree of fibrosis also increases. Therefore, it is easy to understand that liver disease caused by alcohol increases the risk of occurrence as the amount of alcohol is consumed and the period of time is longer.
실제로 알코올 중독자 3 천명의 간 조직을 검사한 결과, 약 40%가 지방간을 보였으며, 5천4백80명을 검사한 경우 약 30%가 알코올성 지방간을 보였다. 이러한 알코올 섭취에 따른 질환의 심한 정도는 주로 음주 섭취량과 관련이 있다. 게다가 알코올을 지속적으로 섭취하는 경우, 에탄올의 체내 대사 결과 생성된 테트라하이드로이소퀴놀린(tetrahydroisoquinoline)이나 테트라하이드로-베타-카볼린(tetrahydro-β-carboline)의 구조가 모르핀(morphine)과 유사하여 금단증상을 유발시키는 결과 에탄올 의존증을 유도한다. 이는 에탄올 대사효소의 감소와 부분적으로 뇌 신경세포의 반응 저하에 의하는 것으로 알려지고 있다. 알코올 의존증은 인체의 알코올 섭취량 및 빈도를 극적으로 증가시켜 상기 설시한 간질환 및 신경, 면역계질환을 단기간에 유발시키는 문제가 있다. In fact, the liver tissues of 3,000 alcoholics showed that about 40% had fatty liver, while 5,480 had about 30% alcoholic fatty liver. The severity of the disease associated with alcohol consumption is mainly related to alcohol consumption. In addition, when alcohol is consumed continuously, the structure of tetrahydroisoquinoline or tetrahydro-beta-carboline, which is produced as a result of ethanol metabolism, is similar to morphine, resulting in withdrawal symptoms. Induces ethanol dependence. This is known to be due to a decrease in ethanol metabolizing enzymes and in part to a decrease in the response of brain neurons. Alcohol dependence causes a drastic increase in the body's alcohol intake and frequency, leading to the above-mentioned liver disease, nerve and immune system diseases in a short time.
섭취한 알코올은 식도 및 구강점막에서도 흡수되며 약 10%는 위장에서 약 90%는 소장에서 흡수된다. 알코올은 3가지 경로를 통해 대사되는 데, 에탄올의 농도가 낮을 때는 위장관 또는 간에 존재하는 알코올탈수소효소(Alcohol dehydrogenase)와 아세트알데히드탈수소효소(Acetaldehyde dehydrogenase)의 작용에 의해, 에탄올의 농도가 높을 때는 소포체에 존재하는 마이크로좀 에탄올 산화체계(MEOS: Microsomal ethanol oxidizing system)에 의해 아세트알데히드와 초산으로 대사되며, 이후 퍼옥시좀(peroxisome)에 존재하는 카탈라제(catalase)의 작용 등을 거쳐 이산화탄소와 물로 최종 분해된다. 이러한 작용기작을 근거해 종래에는 알코올 흡수 억제, 알코올 대사 촉진, 또는 아세트알데히드 농도 저하의 목적으로 숙취해소용 제품을 개발해왔다.Ingested alcohol is also absorbed in the esophagus and oral mucosa, about 10% in the stomach and about 90% in the small intestine. Alcohol is metabolized through three pathways. When the concentration of ethanol is low, alcoholic dehydrogenase and acetaldehyde dehydrogenase, which are present in the gastrointestinal tract or liver, acts. It is metabolized to acetaldehyde and acetic acid by the microsomal ethanol oxidizing system (MEOS) present in it, and then finally decomposed into carbon dioxide and water through the action of catalase present in the peroxisome. do. On the basis of such a mechanism of action, conventionally, products for hangover relief have been developed for the purpose of inhibiting alcohol absorption, promoting alcohol metabolism, or lowering acetaldehyde concentration.
숙취 해소에 관한 종래의 특허는 실크피브로인(대한민국 등록특허 제 0528740호), 오가피, 노근, 모과, 앵두, 저두강(대한민국 등록특허 제 0528388호), 약쑥, 구기자, 건강, 진피, 연근, 지구자, 상심자, 오미자(대한민국 등록특허 제 0512912호), 아스타잔틴, 아스파라긴산(대한민국 등록특허 제 0520985호), 감잎, 감(대한민국 등록특허 제 0504351호), 진피, 백복령, 인진, 갈화, 갈근(대한민국 등록특허 제 0500373호), 아스파라거스, 녹차, 양파, 매실(대한민국 등록특허 제 0496524호), 두릅(대한민국 등록특허 제 0462329호), 콩, 콩나물, 포도씨(대한민국 등록특허 제 0455075호), 지구자 열매의 활성 성분 호베노둘리놀(대한민국 등록특허 제 0452128호), 무, 사철쑥, 칡, 감잎, 삼백초(대한민국 등록특허 제 0451013호), 지구자, 지구목, 헛개나무 혼합물, 갈근, 백하수오, 산약, 작약(대한민국 등록특허 제 0446061호), 백모근, 오디, 토사자, 갈화, 창출, 복분자, 뱀딸기, 방가지풀, (대한민국 등록특허 제 0442771호), 헛개나무 목질부 등(대한민국 등록특허 제 0403720-22호), 갈화, 밀크티슬, 타우린, 울금(대한민국 등록특허 제 0392876호), 나린진, 나린게닌(대한민국 등록특허 제 0375047호), 오리나무, 마가목(대한민국 등록특허 제 0181168호), 헛개나무 열매, 인진호, 갈근, 진피, 창출, 감초(대한민국 공개특허 10-2007-0101443호) 등이 있다. 그러나 특히 알코올의 흡수 억제를 목적으로 하는 발명의 경우 체내 분해되지 않은 잔류 알코올의 지속적인 독성 방출과 체내 pH 변화유발 및 이로 인한 면역학적, 생리학적 또는 신경학적 질환 유발이 문제가 되었다. 또한 알코올의 대사 산물의 신속한 분해를 목적으로 하는 발명의 경우, 알코올이 대사하는 동안 유발되는 두통, 구토, 오한, 설사 등의 숙취 증상 또는 위장관 내 장시간 체류하는 알코올의 독성으로 인해 유발되는 위장관 질환이 발생할 가능성이 증가된다는 문제가 있다. Conventional patents for relieving hangover include silk fibroin (Korean Patent No. 0528740), Ogapi, Nogeun, Chinese quince, cherry tree, low head steel (Korean Patent No. 0528388), wormwood, wolfberry, health, dermis, lotus root, earth , Heartache, Schisandra (Korean Patent No. 0512912), Astaxanthin, Aspartic Acid (Korean Registered Patent No. 0520985), Persimmon Leaf, Persimmon (Korean Registered Patent No. 0504351), Dermis, Baekbokyeong, Injin, Browning, Brown Republic of Korea Patent No. 0500373), Asparagus, Green Tea, Onion, Plum (Republic of Korea Patent No. 0496524), Dharm (Republic of Korea Patent No. 0462329), Beans, Bean Sprouts, Grape Seed (Republic of Korea Patent No. 0455075) Active ingredients of fruit Hobenodullinol (Korean Patent No. 0452128), Radish, Wormwood mugwort, Persimmon leaf, Persimmon leaf, Sambaekcho (Korean Patent No. 0451013), Earth, Sediment, Raspberry mixture, Brown root, Baek Ha Suo, Peony, Peony (Large Republic of Korea Patent No. 0446061), Baekmo Keun, Audi, Earthenware, Galliment, Creation, Bokbunja, Snakeberry, Branberry, (Korean Registered Patent No. 0442771), Wood Chipper, etc. (Korea Registered Patent No. 0403720-22), Brown, Milk Thistle, Taurine, Ulgeum (Republic of Korea Registered Patent No. 0392876), Narinjin, Naringenin (Republic of Korea Registered Patent No. 0375047), Alder, Rowan (Republic of Korea Patent No. 0181168), Nutty Fruit, Injinho, Root , Dermis, creation, licorice (Korea Patent Publication No. 10-2007-0101443) and the like. However, especially for the purpose of inhibiting the absorption of alcohol, there has been a problem of sustained toxic release of undecomposed residual alcohol in the body, induction of pH change in the body, and induction of immunological, physiological or neurological diseases. In addition, in the case of the invention for the purpose of rapid decomposition of the metabolites of alcohol, gastrointestinal diseases caused by the hangover symptoms such as headache, vomiting, chills and diarrhea caused by alcohol metabolism or the toxicity of alcohol staying in the gastrointestinal tract for a long time There is a problem that the probability of occurrence increases.
본 발명은 상기와 같은 문제점을 해결하기 위해, 생약 성분으로서 양강, 갈근, 진피, 창출, 및 감초의 추출물과 말톨을 포함하는 조성물을 이용하여 숙취를 해소하고 나아가 알코올의 섭취로 인한 간질환을 예방, 치료 또는 완화한다. 상세하게는 알코올 흡수를 억제하기보다 대사를 촉진함과 동시에 생성되는 활성산소, 자유분자단과 이들로 인한 산화물인 과산화 지질 생성을 원천적으로 억제하여 알코올 섭취로 인한 제증상을 예방, 치료 내지 완화하는 조성물을 제공하고자 한다.The present invention to solve the above problems, by using the composition containing the extract and maltol of Yanggang, brown root, dermis, creation, and licorice as a herbal ingredient to solve the hangover and further prevent liver disease due to ingestion of alcohol , Treat or relieve. In detail, the composition prevents, treats, or alleviates symptoms caused by alcohol consumption by fundamentally inhibiting the production of free radicals and their peroxides, lipid peroxides, which promote metabolism rather than inhibiting alcohol absorption. To provide.
본 발명은 양강, 진피, 갈근, 창출, 감초의 혼합 생약 추출물 및 말톨을 유효성분으로 함유하는 숙취 해소용 조성물로서, 혼합 생약추출물은 양강 2 내지 8 중량부, 진피 3 내지 24 중량부, 갈근 2 내지 16 중량부, 창출 2 내지 6 중량부 및 감초 2 내지 6 중량부를 함유하며, 말톨은 0.04 내지 1 중량부로 함유되는 것인 조성물을 제공한다.The present invention is a hangover relieving composition containing a mixture of herbal extracts of the Yanggang, dermis, root, creation, licorice and maltol as an active ingredient, the mixed herbal extract is 2 to 8 parts by weight of Yanggang, 3 to 24 parts by weight of dermis To 16 parts by weight, 2 to 6 parts by weight, and 2 to 6 parts by weight of licorice, and maltol is contained in an amount of 0.04 to 1 parts by weight.
또한, 양강, 진피, 갈근, 창출, 감초의 혼합 생약 추출물 및 말톨을 유효성분으로 함유하는 알코올 섭취에 대한 간 보호용 조성물로서, 혼합 생약추출물은 양강 2 내지 8 중량부, 진피 3 내지 24 중량부, 갈근 2 내지 16 중량부, 창출 2 내지 6 중량부 및 감초 2 내지 6 중량부를 함유하며, 말톨은 0.04 내지 1 중량부로 함유되는 것인 조성물을 제공한다.In addition, as a composition for protecting the liver against alcohol intake containing the active herbal extracts of Yangtze, dermis, root, creation, and licorice as an active ingredient, the mixed herbal extracts are 2 to 8 parts by weight of Yanggang, 3 to 24 parts by weight of dermis, It contains 2 to 16 parts by weight of brown root, 2 to 6 parts by weight of produce and 2 to 6 parts by weight of licorice, maltol is contained in 0.04 to 1 part by weight.
본 발명의 조성물은 생약 성분으로서 양강, 갈근 ,진피, 창출, 감초 추출물 및 말톨을 유효성분으로 함유하며, 알코올 섭취 시 혈액 내 알코올 농도를 효과적으로 감소시키고, 각종 숙취 증상의 발생을 억제시키며, 알코올 섭취에 의한 간에서의 과산화 지질 생성을 현저히 억제한다. 따라서 상기 조성물은 숙취 해소제 및 간 보호제로 사용될 수 있으며, 액제, 정제, 캡슐제, 과립제, 환제, 껌의 제형으로 제조 가능하여 음주 전후에 용이하게 섭취할 수 있다.The composition of the present invention contains the medicinal herb, gallium, root, dermis, creation, licorice extract and maltol as active ingredients, effectively reduce the alcohol concentration in the blood when ingesting alcohol, inhibit the occurrence of various hangover symptoms, alcohol consumption Significantly inhibits the production of lipid peroxide in the liver. Therefore, the composition can be used as a hangover relievers and liver protectors, can be prepared in the form of liquids, tablets, capsules, granules, pills, chewing gum can be easily consumed before and after drinking.
한편, 본 발명의 명세서에 기재된 표에 대한 설명은 다음과 같다.In addition, description about the table | surface described in the specification of this invention is as follows.
표 1은 조성물에 포함되는 성분의 함량을 나타낸다.Table 1 shows the contents of the components included in the composition.
표 2는 에탄올을 투여한 마우스의 간에 생성된 과산화 지질을 측정한 것을 나타낸다.Table 2 shows the measurement of lipid peroxide produced in the livers of mice receiving ethanol.
표 3은 알코올을 섭취한 사람의 혈액 중의 알코올 함량을 측정한 것을 나타낸다.Table 3 shows the measurement of the alcohol content in the blood of people who consumed alcohol.
표 4는 숙취 증상을 설문으로 분석한 것이다.Table 4 is a questionnaire analysis of hangover symptoms.
양강은 위를 따뜻하게 하여 위의 소화 기능을 증가하며 위액분비를 촉진하므로 만성 위염, 식욕부진, 구토, 복통, 식체, 속쓰임, 또는 구역 등에 효과가 있다. 특히 신체가 허약하거나 장이 냉하여 발생하는 설사에 좋은 효과가 있어, 찬 음식이나 음료, 과일을 먹고 일어난 복통, 설사에도 치료 효과가 높다. 이외에도 양강은 술독을 풀어 음주 후 대변이 시원치 않을 때, 속이 좋지 않을 때, 또는 아랫배가 당기면서 통증이 있을 때 이를 완화시키는 효과가 있으며, 또한 신장 기능 허약과 냉증으로 인한 정력 감퇴, 또는 이질에도 효력이 있다. 본 발명의 양강(Alpinia officinarum)은 생강과에 속하는 다년생 초본으로 늦여름부터 초가을에 4-6년 생을 캐어 줄기, 잎, 수염뿌리, 인편을 제거하고 근경을 세절하여 햇볕에 말린 것으로 한방에서는 약재로 사용하고 있다. 성분으로는 근경에 0.5~1.5%의 정유가 함유되어 있고 그 주요성분으로는 1,8-시네올, 신나민산(cinnamic acid)의 메틸 에스테르, 피넨(pinene), 카디넨(cadinene) 등이 있다. 이외에 가란골(galangol) 등의 신미성분, 가란진(galangin), 켐페리드(kaempferid), 알피닌(alpinin) 등의 후라보노이드가 분리 및 동정된 것이 보고되어 있다(정보섭 및 신민교, 향약대사전, 영림사, p251, 1998; Hoikusa, The encyclopedia of Wakan-Yaku(Traditional Sino-Japanese Medicine), 1, pp136-137, 1993).Yanggang warms the stomach to increase the digestive function of the stomach and promotes the secretion of gastric juice, so it is effective in chronic gastritis, anorexia, vomiting, abdominal pain, planting, heartburn, or nausea. In particular, it is effective for diarrhea caused by weak body or cold intestine, and it is effective in treating abdominal pain and diarrhea caused by eating cold food, drink, and fruit. In addition, Yanggang has the effect of relieving alcohol poisoning when drinking, stool is uncomfortable, when the stomach is not good, or when the lower abdomen pulls pain, it is also effective in weakening the kidney due to weak kidney function and cold, or dysentery There is this. Yanggang (Alpinia officinarum) of the present invention is a perennial herb belonging to the family of ginger, 4-6 years old in the early autumn from early summer to remove stems, leaves, beard roots, scales and cut the root diameter and dried in the sun as herbs I use it. Ingredients include 0.5-1.5% of essential oils in the rhizome. The main components are 1,8-cineol, methyl esters of cinnamic acid, pinene, and cardinene. . In addition, it has been reported that synamic components such as galangol, galangin, kaempferid, and flavonoids such as alpinin have been isolated and identified (Information and Shinmingyo, Chinese medicine dictionary, Younglim) Gp, p251, 1998; Hoikusa, The encyclopedia of Wakan-Yaku (Traditional Sino-Japanese Medicine), 1, pp136-137, 1993).
갈근(Pueraria lobata Ohwi)은 콩과(Leguminosae)로 주피를 제거한 뿌리이다. 갈근에는 이소플라보노이드(isoflavonoids)로 다이자인(daidzein), 다이진(daidzin), 포모네팀 제니스틴(formonetinm genistein) 등이 함유되어 있다. 또한 트리테르펜(triterpenoids)인 소야사포제놀(soyasapogenol) A와 쿠주사포제놀(Kuzusapogenol) B 등이 함유되어 있어 진정 작용, 하열 작용 및 혈관의 이완 작용을 하며 알코올로 인한 지방간의 생성을 억제하는 약제 중의 하나이다(Kwon HJ et al., World J. Gastroenterol. 11(35):5512-5516, 2005). 갈근에 함유된 다이드진(daidzin)은 알코올의 투여 후 혈중 알코올의 농도를 낮추는 효과가 있으며(Xie CI et al., Alcohol Clin. Exp. Res. 18(6):1443-1447, 1994) 또한 갈근은 인산과 함께 알코올 섭취를 억제시키는 효과가 있다(Carai MA et al., Fitoterapia Aug;71 Suppl 1:S38-42, 2000). 또한 갈근 뿌리의 물 추출물은 알코올 투여로 인한 지방 대사와 항산화 효소의 장애를 제거하는 역할을 한다(Lee JS. et al., Clin. Chim. Acta. 347(1-2):121-128, 2004).Brown root (Pueraria lobata Ohwi) is a legume root with legumes (Leguminosae). The root roots are isoflavonoids, which include diazin, daidzin, and formonetinm genistein. It also contains soyasapogenol A and kuzusapogenol B, which are triterpenoids, soothing, lowering and relaxing blood vessels. (Kwon HJ et al., World J. Gastroenterol. 11 (35): 5512-5516, 2005). Daidzin contained in the roots has the effect of lowering the concentration of alcohol in the blood after the administration of alcohol (Xie CI et al., Alcohol Clin.Exp. Res. 18 (6): 1443-1447, 1994). Brown root has the effect of inhibiting alcohol intake with phosphoric acid (Carai MA et al., Fitoterapia Aug; 71 Suppl 1: S38-42, 2000). In addition, the water extract of the root of roots removes the fat metabolism and antioxidant enzymes caused by alcohol administration (Lee JS. Et al., Clin. Chim. Acta. 347 (1-2): 121-128, 2004 ).
진피는 항알러지 효과, 진정 효과, 항바이러스 효과와 세로토닌의 작용도 향상 시키며 갈근과 진피가 함유된 한약처방이 알코올의 흡수를 저하시켜 음주 후 혈청 알코올의 농도를 저하시킨다는 보고가 있다(Shin BS et al., J. Toxicol. Environ. Health A. 68(23-24):2219-2226, 2005). 진피는 귤(Citrus unshiu Markovich) 또는 그의 근연식물(산초나무과 Rutaceae)의 성숙한 과피이다. 진피에는 정유성분인 d-리모넨(d-limonene), 리나롤(linalool), 및 리날리아세테이트(linalylacetate)와 플라보노이드(flavonoids)인 헤스피리딘(hesperidin), 나린긴(naringin), 포시린(porcirin), 및 노비레틴(nobiletin)와 알카로이드(alkaloid)로서 시네프린(synephrine)이 함유되어 있다. 이러한 진피는 항알레르기 활성(antiallergic activity)이 있고 진정 효과, 항바이러스 효과와 세로토닌(serotonine)의 작용도 향상시킨다는 보고도 있다. 한편 갈근과 진피가 함유된 한약처방이 알코올의 흡수를 저하시켜 음주 후 혈청 알코올의 농도를 저하시켰다고 보고가 있으며(Shin BS et al., J. Toxicol. Environ. Health A. 68(23-24):2219-2226, 2005), 진피가 C형 감염(hepatitis C)에서 간의 손상을 최소화하는 효과가 있다는 보고도 있다(Cyong JC etal., Am. J. Chin. Med. 28(3-4):351-360, 2000). Dermis improves anti-allergic, sedative, antiviral and serotonin effects, and herbal medicines containing root and dermis have been reported to reduce the absorption of alcohol and lower serum alcohol levels after drinking (Shin BS et. al., J. Toxicol.Environ.Health A. 68 (23-24): 2219-2226, 2005). The dermis is the mature rind of the tangerine (Citrus unshiu Markovich) or its plant (Riaceae). The dermis contains essential oils such as d-limonene, linalool, linalilacetate and flavonoids hesperidin, naringin, and porcirin. And synephrine as nobiletin and alkaloid. These dermis have antiallergic activity and have been reported to improve sedative, antiviral and serotonin action. Meanwhile, it has been reported that Chinese medicine prescription containing root and dermis lowered the absorption of alcohol and decreased the concentration of serum alcohol after drinking (Shin BS et al., J. Toxicol. Environ. Health A. 68 (23-24) : 2219-2226, 2005), reports that dermis has the effect of minimizing liver damage in hepatitis C (Cyong JC et al., Am. J. Chin. Med. 28 (3-4): 351-360, 2000).
창출은 수분대사를 촉진시켜 이뇨 및 발한을 촉진시키고 정장에도 효과적이다. 창출은 삽주(Atractylodes japonica Koidzumi)의 뿌리 줄기로 국화과(Compositae)에 속한다. 창출은 아트라세티론(atractylone), 아트라세티레노이드(atractylenolide) I, II, III, 테트라하이드로알란톨시톤(tetrahydroalantolcton), 아부테노리드(abutenolide) B, b-에데스몰(b-eudesmol), 히네솔(hinesol) 등이 함유되어 있다.Creation promotes water metabolism, promotes diuresis and sweating, and is effective for formal wear. Creation is the rhizome of the Atractylodes japonica Koidzumi and belongs to the compositae. Creation can include atractylone, atractylenolide I, II, III, tetrahydroalantotolton, abutenolide B, b-eudesmol, Heinesol and the like.
감초는 항염 및 항궤양 효과가 있고, 소염 효과, 해열 작용, 진통효과가 있다.Licorice has anti-inflammatory and anti-ulcer effect, anti-inflammatory effect, antipyretic effect, analgesic effect.
말톨은 혈당 강하 작용, 노화방지, 또는 항 피로 등의 효과가 있는 강력한 항산화제로, 가향 또는 감미의 목적으로 식품에 첨가되어 사용되고 있다.Maltol is a powerful antioxidant that has effects such as hypoglycemic activity, anti-aging, or anti-fatigue, and is used in addition to food for the purpose of flavoring or sweetening.
이에 본 발명자들은 양강, 진피, 갈근, 창출, 감초의 혼합 생약 추출물 및 말톨을 유효성분으로 함유하는 조성물로서, 혼합 생약추출물은 양강 2 내지 8 중량부, 진피 3 내지 24 중량부, 갈근 2 내지 16 중량부, 창출 2 내지 6 중량부 및 감초 2 내지 6 중량부를 함유하는 추출물에 단순히 가향, 감미의 목적으로 사용되던 말톨에 의해 숙취 해소 및 간 보호에 탁월한 상승적 효과가 있음을 확인하여 본 발명을 완성하고, 이에 상기 목적을 달성하기 위하여, 본 발명은 양강, 진피, 갈근, 창출 및 감초를 물, 주정 또는 이들의 혼합물로 추출한 것에 말톨을 첨가하여 숙취 해소 및 간 보호 효과를 가지는 혼합 생약추출 조성물을 제공한다.Therefore, the inventors of the present invention as a composition containing a mixed herbal extract and maltol of Yanggang, dermis, root, creation, licorice as an active ingredient, the mixed herbal extract is 2 to 8 parts by weight of Yanggang, 3 to 24 parts by weight of dermis, 2 to 16 Completed the present invention by confirming that the extract containing 2 parts by weight, 2 to 6 parts by weight and 2 to 6 parts by weight of licorice has an excellent synergistic effect on the hangover and liver protection by maltol, which was simply used for the purpose of flavoring and sweetening. In order to achieve the above object, the present invention provides a mixed herbal extract composition having a hangover and liver protection effect by adding maltol to the extract of Yanggang, dermis, root, extract and licorice with water, alcohol or mixtures thereof. to provide.
또한, 본 발명은 상기 혼합 생약추출물을 유효성분으로 포함하는 숙취 해소용 건강식품을 제공한다.In addition, the present invention provides a hangover solution for health food comprising the mixed herbal extract as an active ingredient.
아울러, 본 발명은 상기 혼합 생약추출물을 유효성분으로 포함하는 간 보호제를 제공한다.In addition, the present invention provides a hepatoprotectant comprising the mixed herbal extract as an active ingredient.
이하, 본 발명에 대하여 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 양강, 진피, 갈근, 창출 및 감초 추출물에 말톨을 첨가한 조성물이 숙취 해소 및 간 보호에 미치는 영향을 조사하기 위하여 건조된 양강, 진피, 갈근, 창출 및 감초를 하기와 같은 중량부로 평량하여 추출하였다.In order to investigate the effect of the composition of maltol added to Yangtze, dermis, roots, extract and licorice extract on hangover and liver protection, Extracted by.
추출 방법은Extraction method
1) 물, 주정 또는 이들의 혼합물을 이용하여 양강, 진피, 갈근, 창출 및 감초에서 추출물을 획득하는 단계;1) obtaining an extract from Yanggang, dermis, reeds, creation and licorice using water, alcohol or mixtures thereof;
2) 단계 1)을 반복하여 2차 추출물을 획득하는 단계;2) repeating step 1) to obtain a secondary extract;
3) 단계 1)의 1차 추출물과 단계 2)의 2차 추출물을 혼합하여 여과하는 단계;3) mixing and filtering the primary extract of step 1) and the secondary extract of step 2);
4) 여액을 감압 하에서 농축하고 말톨을 첨가하는 단계로 구성된다. 4) concentrating the filtrate under reduced pressure and adding maltol.
단계 1)과 2)에서 사용하는 추출 용매는 사용되는 생약들의 무게의 5 내지 10배인 것이 바람직하다. 추출 온도는 80 내지 100℃, 추출 시간은 4 내지 12시간인 것이 바람직하다.The extraction solvent used in steps 1) and 2) is preferably 5 to 10 times the weight of the herbal medicines used. It is preferable that extraction temperature is 80-100 degreeC, and extraction time is 4-12 hours.
본 발명의 생약들의 혼합 비율은 양강 2 내지 8 중량부, 진피 3 내지 24 중량부, 갈근 2 내지 16 중량부, 창출 2 내지 6 중량부 및 감초 2 내지 6 중량부를 함유하는 것이 바람직하며, 말톨은 0.04 내지 1 중량부로 함유되는 것이 바람직하다.The mixing ratio of the herbal medicines of the present invention preferably contains 2 to 8 parts by weight of Yanggang, 3 to 24 parts by weight of dermis, 2 to 16 parts by weight of roots, 2 to 6 parts by weight, and 2 to 6 parts by weight of licorice. It is preferably contained in 0.04 to 1 part by weight.
본 발명의 조성물이 숙취 해소 및 간 보호 효과가 있는지를 알아보기 위하여 마우스에 비교예 1, 비교예 2, 실시예 1 ~ 8, 말톨을 섭취시키고 절식시킨 후, 급성 중독이 가능한 용량의 에탄올을 투여하여 12시간 후에 간에 생성된 과산화지질의 량을 측정하여 비교하였다.In order to find out whether the composition of the present invention has a hangover and liver protection effect, mice are fed with Comparative Example 1, Comparative Example 2, Examples 1 to 8, maltol, and fasted, followed by administration of ethanol in a dose capable of acute poisoning. After 12 hours, the amount of lipid peroxide produced in the liver was measured and compared.
표 2에서 보는 바와 같이 생약만으로 구성된 비교예 1, 비교예 2, 말톨은 과산화 지질 생성을 각각 36.6%, 34.8%, 58.2% 억제한 반면, 본 발명의 실시예 1∼8은 각각 92.8%, 95.4%, 93.8%, 89.2%, 86.6%, 88.7%, 91.3%. 89.7% 억제하였다. 종합하면 비교예 1, 비교예 2에서와 같은 종래의 기술에 비교하여 생약 혼합추출물과 말톨을 같이 처방한 본 발명의 혼합 생약추출물이 에탄올에 의한 간 손상을 억제하여 현저한 간 보호 효과가 있음을 알 수 있다.As shown in Table 2, Comparative Example 1, Comparative Example 2, and Maltol, which are composed of only herbal drugs, inhibited lipid peroxide production by 36.6%, 34.8%, and 58.2%, respectively, while Examples 1 to 8 of the present invention were 92.8% and 95.4, respectively. %, 93.8%, 89.2%, 86.6%, 88.7%, 91.3%. 89.7% inhibition. Taken together, it was found that the mixed herbal extract of the present invention, which was prescribed with the mixed herbal extract and maltol as compared to the conventional techniques as in Comparative Example 1 and Comparative Example 2, suppresses liver damage caused by ethanol and has a significant liver protection effect. Can be.
숙취해소 효과를 평가하기 위하여, 건강한 남성들에게 본 발명의 종래 기술에 해당하는 비교예 2, 본 발명의 실시예 1, 실시예 5를 대표적으로 선택하여 섭취시킨 후, 소주를 음용하게 하여 일정 시간마다 혈액 중의 알코올 농도를 측정하고 숙취 증상을 설문지를 활용하여 조사하였다. 표 3에서 보는 바와 같이 종래 기술에 해당하는 비교예 2가 약간의 혈중 알콜 농도 감소효과를 보이는 반면, 본 발명의 실시예 1, 실시예 5을 섭취한 그룹은 대조군과 비교예 2에 비하여 혈중 알코올 농도가 현저하게 낮아졌음을 알 수 있다. 또한, 음주 5시간 후와 14시간 후 대표적인 숙취 증상인 졸음, 두통, 어지러움, 무력감, 속쓰림, 집중곤란, 평소보다 자극에 민감함이 대조군은 심한 정도의 점수를 보이며 종래 기술에 해당하는 비교예 2섭취군은 미약한 해소 효과를 나타내는 데 반하여, 본 발명의 실시예 1, 실시예 5를 섭취한 그룹은 보통이거나 증상이 없는 수준의 점수를 보여주어 현저한 숙취증상 해소 효과를 보여 주었다. 종합하면 종래 기술에 해당하는 생약 혼합추출물에 비교하여 생약 혼합추출물과 말톨을 같이 처방한 본 발명의 혼합 생약추출물이 음주 후의 숙취증상 해소 효과에 매우 탁월함을 알 수 있다.In order to evaluate the hangover elimination effect, healthy males were selected and ingested representatively Comparative Example 2, Examples 1 and 5 of the present invention to the prior art of the present invention, and then drink soju for a certain time The alcohol concentration in the blood was measured and the hangover symptoms were investigated using the questionnaire. As shown in Table 3, while Comparative Example 2 corresponding to the prior art shows a slight decrease in blood alcohol concentration, the group ingesting Examples 1 and 5 of the present invention has blood alcohol compared to the control and Comparative Example 2. It can be seen that the concentration is significantly lower. In addition, 5 hours after drinking and 14 hours after the typical hangover symptoms of drowsiness, headache, dizziness, helplessness, heartburn, difficulty in congestion, more sensitive than usual stimulation, the control group showed a severe score and Comparative Example 2 corresponding to the prior art The ingested group showed a weak relieving effect, whereas the groups ingesting Examples 1 and 5 of the present invention showed a moderate or asymptomatic level of scores, showing a significant hangover symptoms. Taken together, it can be seen that the mixed herbal extract of the present invention, which is prescribed with the mixed herbal extract and maltol as compared to the herbal extract corresponding to the prior art, is very excellent in the hangover symptoms after drinking.
성인의 섭취량은 혼합 생약추출물 200 내지 3,500mg을 1회, 하루 2-3회 섭취하는 것이 바람직하다. 본 발명에 사용되는 원재료는 식품 원료로 사용할 수 있도록 허가된 안전한 것이며 이들의 추출물도 허용 가능한 범위 내에서 안전하게 섭취할 수 있다.Adult intake is preferably a mixed herbal extract 200 to 3,500mg once, 2-3 times a day. The raw materials used in the present invention are safe and licensed to be used as food ingredients, and their extracts can also be safely consumed within an acceptable range.
본 발명의 혼합 생약추출물을 유효성분으로 함유하는 숙취 해소용 조성물은 경구적으로 섭취하며, 섭취하기 용이하도록 혼합 생약추출물의 유효량에 약제학적으로 허용 가능한 통상적인 희석제, 활탁제, 결합제, 붕해제, 감미제, 안정제, 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등의 첨가제 중 1 이상을 선택하여, 통상적인 약제학적 제형 즉 액제, 현탁제, 캡슐제, 정제, 껌, 환제, 과립제의 제형으로 제조할 수 있으나, 이에 한정되는 것은 아니다.Hangover-relieving composition containing the mixed herbal extract of the present invention as an active ingredient is orally ingested, and conventional diluents, suspending agents, binders, disintegrating agents, which are pharmaceutically acceptable in an effective amount of the mixed herbal extract to facilitate ingestion, Used in sweeteners, stabilizers, nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated drinks By selecting one or more of additives such as carbonation agent, it can be prepared in conventional pharmaceutical formulations, that is, liquid, suspension, capsule, tablets, gums, pills, granules, but is not limited thereto.
이하, 본 발명을 실시예, 실험예에 의해 상세히 설명한다. 단, 하기 실시예, 실험예는 본 발명을 예시하는 것일 뿐, 하기의 실시예가 특허 청구의 범위에 기재된 발명의 내용을 한정하는 것은 아니다.Hereinafter, the present invention will be described in detail by Examples and Experimental Examples. However, the following Examples and Experimental Examples merely illustrate the present invention, and the following Examples do not limit the contents of the invention described in the claims.
한편, 표 1은 조성물에 포함되는 성분의 함량을 표로 도시한 것이다.On the other hand, Table 1 is a table showing the content of the components included in the composition.
Dry Material (g)
비교예 1Comparative Example 1
한약건재상에서 구입한 진피 600g, 갈근 400g, 창출 150g, 감초 150g를 한약추출기에 넣고 정제수 10L를 가하여 95℃에서 4시간 가열 추출(1차 추출액), 잔사에 정제수 10L를 가하여 95℃에서 4시간 가열 추출(2차 추출액) 한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 농축분말 220g을 얻었다.
600 g of dermis, 400 g of brown root, 150 g of licorice, and 150 g of licorice purchased from Chinese herbal medicines were placed in a herbal extractor, and 10 liters of purified water was added.The extract was heated at 95 ℃ for 4 hours (primary extract), and 10 liters of purified water was added to the residue. After extraction (secondary extract), the first and second extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to obtain 220 g of concentrated powder.
비교예 2Comparative Example 2
한약건재상에서 구입한 양강 200g, 진피 600g, 갈근 400g, 창출 150g, 감초 150g를 한약추출기에 넣고 정제수 10L를 가하여 95℃에서 4시간 가열 추출(1차 추출액), 잔사에 정제수 10L를 가하여 95℃에서 4시간 가열 추출(2차 추출액) 한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 농축분말 255g을 얻었다.
200g, dermis 600g, brown root 400g, 150g, licorice 150g, which were purchased from Chinese herbal medicines, were added to a herbal extractor, and 10L of purified water was added for 4 hours at 95 ℃ for extraction (primary extract), and 10L of purified water was added to the residue at 95 ℃. After 4 hours of heat extraction (secondary extract), the primary and secondary extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to obtain 255 g of concentrated powder.
실시예 1Example 1
한약건재상에서 구입한 양강 400g, 진피 1,200g, 갈근 800g, 창출 300g, 감초 300g를 한약추출기에 넣고 정제수 20L를 가하여 95℃에서 4시간 가열 추출(1차 추출액), 잔사에 정제수 20L를 가하여 95℃에서 4시간 가열 추출(2차 추출액)항 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 40g을 넣고 계속 농축하여 농축분말 530g을 얻었다.
400 g of Yanggang, 1,200 g of dermis, 800 g of dried root, 800 g of dried root, 300 g of licorice, 300 g of licorice were added to the herbal extractor, and 20 L of purified water was added for 4 hours, followed by heating extraction at 95 ° C (primary extract), and 20 L of purified water was added to the residue. After 4 hours of heat extraction (secondary extract), the primary and secondary extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 40 g of maltol was added thereto and concentrated to obtain 530 g of concentrated powder.
실시예 2Example 2
양강 40g, 진피 280g, 갈근 120g, 창출 40g, 감초 120g를 한약추출기에 넣고 정제수 3L를 가하여 80℃에서 12시간 가열 추출(1차 추출액), 잔사에 정제수 3L를 가하여 80℃에서 12시간 가열 추출(2차 추출액)한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 12g을 넣고 계속 농축하여 농축분말 115g을 얻었다.
Put 40g of Yanggang, 280g of dermis, 120g of root, 40g of liquor, 120g of licorice into a herbal extractor, add 3L of purified water and extract it by heating at 80 ℃ for 12 hours (primary extract), and add 3L of purified water to the residue and heat-extract at 80 ℃ for 12 hours. Secondary extract), and the primary and secondary extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 12 g of maltol was added thereto and concentrated to obtain 115 g of concentrated powder.
실시예 3Example 3
양강 160g, 진피 120g, 갈근 40g, 창출 40g, 감초 240g를 한약추출기에 넣고 정제수 6L를 가하여 100℃에서 15시간 가열 추출(1차 추출액), 잔사에 정제수 6L를 가하고 100℃에서 12시간 가열 추출(2차 추출액) 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 10g을 넣고 계속 농축하여 농축분말 125g을 얻었다.
Put 160g of Yanggang, 120g of dermis, 40g of root, 40g of creation, 240g of licorice into a herbal extractor, add 6L of purified water and heat extract at 100 ℃ for 15 hours (primary extract), add 6L of purified water to residue and heat extract at 100 ℃ for 12 hours. Secondary extract) The first and second extracts were combined, cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 10 g of maltol was added thereto and concentrated to obtain 125 g of concentrated powder.
실시예 4Example 4
양강 60g, 진피 300g, 갈근 80g, 창출 120g, 감초 40g를 한약추출기에 넣고 정제수 4L를 가하여 90℃에서 12시간 가열 추출(1차 추출액), 잔사에 정제수 4L를 가하여 90℃에서 12시간 가열 추출(2차 추출액)한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 8g을 넣고 계속 농축하여 60브릭스 농축액 260g을 얻었다.
60g of Yanggang, 300g of dermis, 80g of root, 80g of creation, 120g of licorice and 40g of licorice are added to a herbal extractor, and 4L of purified water is added. The extract is heated at 90 ℃ for 12 hours (primary extract) and 4L of purified water is added to the residue. Secondary extract), and the primary and secondary extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 8 g of maltol was added thereto and concentrated to obtain 260 g of a 60 brim concentrate.
실시예 5Example 5
양강 120g, 진피 200g, 갈근 100g, 창출 60g, 감초 120g를 한약추출기에 넣고 정제수 5L를 가하고 90℃에서 8시간 가열 추출하고(1차 추출액), 잔사에 정제수 4L를 가하고 90℃에서 7시간 가열 추출하고 (2차 추출액) 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 15% 용액이 되었을 때 말톨 2g을 넣고 감압열풍건조 (스프레이 드라이)하여 분말 100g을 얻었다.
120 g of Yanggang, 200 g of dermis, 100 g of root, 60 g of liquor, 120 g of licorice are added to a herbal extractor, 5 L of purified water is added and extracted by heating at 90 ° C. for 8 hours (primary extract), 4 L of purified water is added to the residue and heated to 90 ° C. for 7 hours. The secondary and primary extracts were combined, cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 15% solution, and 2 g of maltol was added thereto, followed by drying under reduced pressure (spray drying) to obtain 100 g of powder.
실시예 6Example 6
양강 100g, 진피 140g, 갈근 200g, 창출 80g, 감초 80g를 한약추출기에 넣고 정제수 5L를 가하여 95℃에서 6시간 가열 추출(1차 추출액), 잔사에 정제수 5L를 가하여 95℃에서 시간 가열 추출(2차 추출액)한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 4g을 넣고 계속 농축하여 농축분말 105g을 얻었다.
Put 100g of Yanggang, 140g of dermis, 200g of root, 80g of liquor, 80g of licorice in a herbal extractor, add 5L of purified water and heat extract at 95 ℃ for 6 hours (primary extract), and add 5L of purified water to the residue and heat-extract at 95 ℃ (2 Primary and secondary extracts, and then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 4 g of maltol was added thereto and concentrated to obtain 105 g of concentrated powder.
실시예 7Example 7
양강 80g, 진피 240g, 갈근 160g, 창출 60g, 감초 60g을 추출기에 넣고 70% 주정 5L를 가하고 95℃에서 5시간 가열 추출(1차 추출액), 잔사에 70%주정 5L를 가하고 95℃에서 시간 가열 추출(2차 추출액)한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 10g을 넣고 계속 농축하여 농축분말 101g을 얻었다.
80 g of Yanggang, 240 g of dermis, 160 g of root, 60 g of liquor, 60 g of licorice are added to the extractor, and 5 L of 70% spirits are extracted.The mixture is heated for 5 hours at 95 ° C (primary extract), 5 L of 70% alcohol is added to the residue, and heated at 95 ° C. After extraction (secondary extract), the primary and secondary extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 10 g of maltol was added thereto and concentrated to obtain 101 g of concentrated powder.
실시예 8Example 8
양강 80g, 진피 140g, 갈근 160g, 창출 60g, 감초 60g을 추출기에 넣고 70% 주정 4L를 가하고 95℃에서 5시간 가열 추출(1차 추출액), 잔사에 95%주정 4L를 가하고 95℃에서 시간 가열 추출(2차 추출액)한 후 1차, 2차 추출액을 합하여 실온으로 냉각한 후 여과하였다. 여액을 65℃에서 감압 농축하여 40% 용액이 되었을 때 말톨 6g을 넣고 계속 농축하여 농축분말 92g을 얻었다.
80 g of Yanggang, 140 g of dermis, 160 g of root, 60 g of liquor, 60 g of licorice are added to the extractor, and 70% alcohol 4L is added and heated extraction (primary extract) at 95 ° C for 5 hours, 95% alcohol 4L is added to the residue, and heated at 95 ° C. After extraction (secondary extract), the primary and secondary extracts were combined, cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure at 65 ° C. to a 40% solution, and 6 g of maltol was added thereto and concentrated to obtain 92 g of concentrated powder.
실시예 9 Example 9
액제Liquid
실시예 1의 혼합 생약추출물 50g, 비타민 B1염산염 0.25g, 리보플라빈 0.25g, 니코틴산아드 0.5g, 벌꿀 50g에 정제수를 가하여 2,500mL 부피로 제조한 후 통상의 방법에 따라 병에 10mL씩 충진하여 액제를 제조하였다.
50 g of the mixed herbal extract of Example 1, 0.25 g of vitamin B1 hydrochloride, 0.25 g of riboflavin, 0.5 g of nicotinic acid, and 50 g of honey were added to prepare a volume of 2,500 mL, followed by filling 10 mL into the bottle according to a conventional method. Prepared.
실시예 10Example 10
연질캡슐제Soft Capsule
실시예 1의 혼합 생약추출물 50g, 소맥배아유 20g, 대두유 40g, 및 백납 5g을 혼합하고 통상의 방법에 따라 1연질캡슐당 500mg 씩 충전하여 연질캡슐을 제조하였다.
50 g of the mixed herbal extract of Example 1, 20 g of wheat germ oil, 40 g of soybean oil, and 5 g of white lead were mixed, and a soft capsule was prepared by filling 500 mg per soft capsule according to a conventional method.
실시예 11Example 11
과립제Granule
실시예 1의 혼합 생약추출물 50g, 비타민 B1염산염 0.25g, 리보플라빈 0.25g, 니코틴산아드 0.5g, 비타민 C 1g, 카르복시메틸 셀룰로오스 칼슘 2g, 결정셀룰로오스 150g, 및 카르복시메틸 셀룰로오스 나트륨 5g을 혼합하고 통상의 방법에 따라 과립제를 제조하여 알루미눔 포치에 3g씩 충진하였다.50 g of the mixed herbal extract of Example 1, 0.25 g of vitamin B1 hydrochloride, 0.25 g of riboflavin, 0.5 g of nicotinate, 1 g of vitamin C, 2 g of carboxymethyl cellulose calcium, 150 g of crystalline cellulose, and 5 g of sodium carboxymethyl cellulose were mixed. A granule was prepared according to the present invention and filled with 3 g of aluminum porch.
실시예 12Example 12
환제Pill
실시예 1의 혼합 생약추출물 50g, 비타민 B1염산염 0.25g, 리보플라빈 0.25g, 니코틴산아드 0.5g, 비타민 C 1g, 카르복시메틸 셀룰로오스 칼슘 2g, 결정셀룰로오스 100g, 카르복시메틸 셀룰로오스 나트륨 2g, 및 벌꿀 90g을 혼합하여 통상의 방법에 따라 1환당 1g씩의 환제를 제조하였다
50 g of the mixed herbal extract of Example 1, 0.25 g of vitamin B1 hydrochloride, 0.25 g of riboflavin, 0.5 g of nicotinate, 1 g of vitamin C, 2 g of carboxymethyl cellulose calcium, 100 g of crystalline cellulose, 2 g of sodium carboxymethyl cellulose, and 90 g of honey According to the conventional method, 1 g of pills were prepared per ring.
실시예 13Example 13
정제refine
실시예 1의 혼합 생약추출물 50g, 비타민 B1염산염 0.25g, 리보플라빈 0.25g, 니코틴산아드 0.5g, 비타민 C 5g, 옥수수전분 100g, 카르복시메틸 셀룰로오스 나트륨 2g, 및 스테아린산 마그네슘 5g을 혼합하여 통상의 방법에 따라 1정 당 500mg의 정제를 제조하였다.
50 g of the mixed herbal extract of Example 1, 0.25 g of vitamin B1 hydrochloride, 0.25 g of riboflavin, 0.5 g of nicotinic acid, 5 g of vitamin C, 100 g of corn starch, 2 g of sodium carboxymethyl cellulose, and 5 g of magnesium stearate were mixed according to a conventional method. 500 mg tablets were made per tablet.
실시예 14Example 14
츄잉껌Chewing gum
실시예 1의 혼합생약추출물 50g, 젤라틴 200g, 설탕 300g, 물엿 200g, 껌 베이스 200g(껌 베이스는 초산비닐수지 300부, 에스테르껌 250부, 폴리이소부티렌 100부, 글리세린지방산에스테르 300부, 마이크로크리스탈린왁스 100부, 탈크 150부의 비율로 제조한 것)을 통상의 껌 졔조공정에 따라 츄잉껌을 제조하고, 한 알당 6g 되게 성형하였다.
50 g of the mixed herbal extract of Example 1, 200 g of gelatin, 300 g of sugar, 200 g of starch syrup, 200 g of gum base (300 parts of vinyl acetate resin, 250 parts of ester gum, 100 parts of polyisobutyrene, 300 parts of glycerin fatty acid ester, micro 100 parts of crystallin wax and 150 parts of talc) were prepared according to a conventional gum making process, and chewing gum was molded to 6 g per grain.
실험예 1Experimental Example 1
본 발명의 조성물이 알코올 급성투여로 유도되는 간 독성에 대하여 간 보호 효과를 발휘하는 지 여부를 알기 위하여, 체중 20 내지 24g의 ICR계 수컷 마우스 8마리에 비교예 1, 비교예 2, 실시예 1-8에서 제조한 혼합 생약추출물 500mg을 10mL 식염수에 분산시킨 것(단, 실시예 4는 1,000mg을 10mL식염수에 분산한 것)을 0.2mL/20g체중 및 말톨 60mg/Kg체중으로 1일 1회 3일간 경구 투여하였다. 이어서 8시간 절식시킨 후 혼합 생약추출물 0.2mL/20g체중을 경구 투여하고 30분 후 45% 에탄올 0.3mL/20g체중을 경구 투여한 뒤, 12시간 후 간 조직 내의 과산화 지질을 TBA법으로 정량하여(Anal. Biochem. 95, 351, 1978) 그 결과를 표 1에 나타내었다. 적출한 간은 그룹별로 합하여 파쇄하여 사용하였다. In order to know whether the composition of the present invention exerts a hepatoprotective effect against hepatotoxicity induced by acute alcohol administration, 8 ICR male mice weighing 20 to 24 g were compared to Comparative Example 1, Comparative Example 2, and Example 1 500 mg of the mixed herbal extract prepared in -8 was dispersed in 10 mL saline (Example 4, 1,000 mg was dispersed in 10 mL saline) in 0.2 mL / 20 g body weight and Maltol 60 mg / Kg body weight once a day. Administration was oral for 3 days. After fasting for 8 hours, 0.2 mL / 20 g of mixed herbal extracts were orally administered and 30 minutes after oral administration of 0.3 mL / 20 g of 45% ethanol, and 12 hours later, lipid peroxide in liver tissue was quantified by TBA method ( Anal. Biochem. 95, 351, 1978) The results are shown in Table 1. The extracted livers were combined and broken up into groups.
억제율은 다음 식에 의하여 계산하였다.Inhibition rate was calculated by the following equation.
억제율 = 〔1-(에탄올 투여대조 흡광도-시료 투여군 흡광도)/(에탄올 투여대조 흡광도-정상 동물군 흡광도)〕 x 100 %
Inhibition rate = [1- (ethanol control control absorbance-sample absorbance) / (ethanol control control absorbance-normal animal absorbance)] x 100%
흡광도/g 습윤 간 중량)Lipomass Peroxide (at 532 nm
Absorbance / g wet liver weight)
(%)Inhibition rate
(%)
실험예 2Experimental Example 2
본 발명의 비교예 2, 실시예 1과 실시예 5의 조성물을 대표 시료로 선택하여 섭취시키고, 음주 후 혈액 중에 알코올 농도에 미치는 영향을 혈중 알코올 농도로, 숙취 증상에 미치는 영향을 설문을 통하여 조사하였다.The composition of Comparative Example 2, Example 1 and Example 5 of the present invention is selected as a representative sample, and the effect of alcohol on blood alcohol concentration after drinking alcohol is investigated through the questionnaire on the effects on hangover symptoms. It was.
나이 30 내지 40세, 체중 65 내지 75Kg의 남성 24명을 선발하여 무작위로 6명씩 세 그룹으로 나누고, 점심식사를 하지 않고 오후 5시 30분에 비교예 2, 실시예 1, 실시예 5에서 제조한 혼합 생약추출물 50mg/mL 생리식염수/Kg체중을 각자의 체중에 적합하도록 계산하여 한번에 섭취시킨다. 대조군은 동량의 생리식염수를 섭취시킨다.24 males aged 30 to 40 years old and weighing 65 to 75 kg were randomly divided into three groups of six randomly, and prepared in Comparative Examples 2, 1 and 5 at 5:30 pm without lunch. One mixed herbal extract 50mg / mL physiological saline / Kg body weight is calculated to be suitable for each body weight and consumed at once. The control group consumes the same amount of normal saline.
알코올 섭취량은 알코올 1.5g/Kg 체중으로 정하고(20% 소주 450mL/60Kg 체중), 투여군 및 대조군 모두 6시부터 1.5시간 동안 10분 간격으로 정해진 알코올을 섭취시킨다. 안주는 투여군, 대조군 모두에게 새우깡 30g 씩을 섭취시켰다. 음주 완료 후 각자에게 배정된 비교예 2, 실시예 1, 실시예 5의 혼합 생약추출물을 음주 전에 섭취한 것과 동량을 섭취시킨다. 음주 후 30분부터 5시간 동안 일정 간격으로 팔 정맥에서 채혈하여 성분 분석을 위한 전처리를 한 후 알코올 정량키트를 사용하여 혈중 알코올을 측정한 뒤 그 결과를 표 3에 나타내었다. Alcohol intake is set at 1.5g / Kg body weight of alcohol (20% soju 450mL / 60Kg body weight), and both the administration group and the control group are ingested at 10 minute intervals for 6 hours from 6 hours. Snacks were ingested 30g each shrimp and control group. After the drinking is completed, the same amount of the mixed herbal extracts of Comparative Example 2, Example 1, and Example 5 assigned to each person is taken before drinking. After drinking, blood was collected from the arm vein at regular intervals for 30 minutes to 5 hours, followed by pretreatment for component analysis, and then the alcohol was measured using an alcohol quantitative kit.
숙취증상 해소 효과를 평가하기 위하여 가장 일반적인 숙취 증상을 적시하고 음주자의 반응이 아주 심한 경우 5점, 심한 경우 4점, 약간 심한 경우 3점, 보통인 경우 2점, 없는 경우 1점으로 한 설문서를 음주 후 5시간, 14시간 후 2회에 걸쳐 작성토록 하여 비교 검토하였다. 그 결과를 표 4에 나타내었다.
In order to evaluate the effects of hangover symptoms, the most common hangover symptoms should be timed and a questionnaire with 5 points for severe reactions, 4 points for severe cases, 3 points for severe cases, 2 points for moderate cases, and 1 point for none. Two times after drinking and 14 hours after drinking, the study was completed. The results are shown in Table 4.
30분 후Start drinking
30 minutes later
1시간 후Start drinking
1 hour later
2시간 후Start drinking
2 hours later
3시간 후Start drinking
3 hours later
5시간 후Start drinking
5 hours later
Symptom
5 hours after drinking
14 hours after drinking
Claims (13)
2) 상기 단계 1)을 반복하여 2차 추출물을 획득하는 단계;
3) 상기 단계 1)의 1차 추출물과 상기 단계 2)의 2차 추출물을 혼합하여 여과하는 단계; 및
4) 여액을 감압 하에서 농축하고 말톨을 첨가하는 단계;
를 포함하는 것을 특징으로 하는 제1항 또는 제2항에 따른 식품 조성물을 제조하는 방법.1) obtaining an extract from Yanggang, dermis, reeds, creation and licorice using water, alcohol or mixtures thereof;
2) repeating step 1) to obtain a secondary extract;
3) mixing and filtering the primary extract of step 1) and the secondary extract of step 2); And
4) concentrating the filtrate under reduced pressure and adding maltol;
Method for producing a food composition according to claim 1 or 2, characterized in that it comprises a.
The food composition of claim 1 or 2, wherein the composition is prepared in the form of a gum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120077942A KR101365794B1 (en) | 2012-07-17 | 2012-07-17 | The improved composition for relieving hangovers and protecting a liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120077942A KR101365794B1 (en) | 2012-07-17 | 2012-07-17 | The improved composition for relieving hangovers and protecting a liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140010831A KR20140010831A (en) | 2014-01-27 |
| KR101365794B1 true KR101365794B1 (en) | 2014-02-20 |
Family
ID=50143347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120077942A KR101365794B1 (en) | 2012-07-17 | 2012-07-17 | The improved composition for relieving hangovers and protecting a liver |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101365794B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180013397A (en) | 2016-07-29 | 2018-02-07 | 천지인초 주식회사 | Food composition comprising the mixed herbal extract as an active ingredient |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109258908A (en) * | 2018-10-31 | 2019-01-25 | 方林 | A kind of preparation method of rose chewing gum |
| KR102043813B1 (en) * | 2018-12-26 | 2019-11-12 | 이창원 | Composition for liver protection against alcoholic liver damage |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010026440A (en) * | 1999-09-06 | 2001-04-06 | 박명환 | Composition for alcohol-detoxification |
| KR20020041515A (en) * | 2000-11-28 | 2002-06-03 | 김현영 | Chinese Medicine Composition for Dissolving Suffer from Aftereffects of Drink and Method of Preparing the Same |
| KR100853078B1 (en) | 2007-03-26 | 2008-08-19 | 김혁 | A method for preparation of a hurb composition for removing hangover |
-
2012
- 2012-07-17 KR KR1020120077942A patent/KR101365794B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010026440A (en) * | 1999-09-06 | 2001-04-06 | 박명환 | Composition for alcohol-detoxification |
| KR20020041515A (en) * | 2000-11-28 | 2002-06-03 | 김현영 | Chinese Medicine Composition for Dissolving Suffer from Aftereffects of Drink and Method of Preparing the Same |
| KR100853078B1 (en) | 2007-03-26 | 2008-08-19 | 김혁 | A method for preparation of a hurb composition for removing hangover |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180013397A (en) | 2016-07-29 | 2018-02-07 | 천지인초 주식회사 | Food composition comprising the mixed herbal extract as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140010831A (en) | 2014-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100574097B1 (en) | Functional food compositions having the effect on eliminating an alcoholic hangover and improvement of liver function | |
| KR100404979B1 (en) | Drink for getting rid of the aftereffects of the night's drink and manufacturing method thereby | |
| CN103203008A (en) | Pharmaceutical composition for sobering up and preparation method thereof | |
| CN103610803B (en) | A kind of liver-protecting and alcoholism-relieving Chinese medicine composition | |
| KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
| CN113456725A (en) | Product for relieving alcoholism and preparation method thereof | |
| CN103933509B (en) | For treating medicine of fresh-water fishes fish molds and preparation method thereof | |
| KR101365794B1 (en) | The improved composition for relieving hangovers and protecting a liver | |
| CN101745087A (en) | Composition with effects of relieving alcoholism and preventing drunkenness and preparation method thereof | |
| KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
| KR20100041284A (en) | The method and the beverage which are good for getting out of drunken condition and for liver function | |
| CN105796753A (en) | Hepatoprotection traditional Chinese medicine composition and preparation method thereof | |
| CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
| KR20130029284A (en) | Composition of healthy foods for treatment of dementia | |
| KR20020078467A (en) | Drink for tonic liver and Manufacture process the same. | |
| CN101745042B (en) | Composition with effects of relieving alcoholism and protecting liver and preparation method thereof | |
| CN108419869A (en) | Fiery composition, beverage and preparation method thereof under a kind of heat-clearing toxin expelling | |
| KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
| CN107158299A (en) | It is a kind of that there is composition of enhancing learning memory function and preparation method thereof | |
| CN111905087A (en) | Health-care product composition for dispelling effects of alcohol and protecting liver | |
| CN100475065C (en) | Beverage for eliminating alcoholism and preventing alcohol liver and preparation method thereof | |
| KR101375686B1 (en) | Oral disintegrating tablet for suppressing appetite and menufacturing method thereof | |
| CN113181205B (en) | Pharmaceutical composition comprising NMN and use thereof | |
| CN109106842B (en) | A medicine for stopping smoking and its preparation method | |
| KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170113 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180123 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20200115 Year of fee payment: 7 |